Open AccessModeling Combination Hepatitis C Virus Treatment and Prevention Strategies in a Network of People Who Inject Drugs in the United States
Author(s) -
Alexei Zelenev,
Jianghong Li,
Portia Shea,
Robert Hecht,
Frederick L. Altice
Publication year - 2020
Publication title -
clinical infectious diseases/clinical infectious diseases (online. university of chicago. press)
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.44
H-Index - 336
eISSN - 1537-6591
pISSN - 1058-4838
DOI - 10.1093/cid/ciaa142
Subject(s) - medicine , hepatitis c virus , syringe , treatment as prevention , hepatitis c , methadone , buprenorphine , psychological intervention , virology , human immunodeficiency virus (hiv) , virus , pharmacology , viral load , opioid , psychiatry , antiretroviral therapy , receptor
Hepatitis C virus (HCV) treatment as prevention (TasP) strategies can contribute to HCV microelimination, yet complimentary interventions such as opioid agonist therapies (OAT) with methadone or buprenorphine and syringe services programs (SSPs) may improve the prevention impact. This modeling study estimates the impact of scaling up the combination of OAT and SSPs with HCV TasP in a network of people who inject drugs (PWID) in the United States.